Tara has a robust Intellectual Property practice focusing on complex patent litigation, counseling, opinion work and due diligence in the life sciences and pharmaceutical industries, with specific expertise in the Hatch-Waxman Amendments to the Food, Drug, and Cosmetic Act and the Biologics Price Competition and Innovation Act (BPCIA). Tara partners with clients to navigate complex patent and regulatory issues to deliver forward-looking IP and regulatory strategies that align with commercial goals.
Tara represents branded, generic and biosimilars companies in high-stakes litigation, integrating deep knowledge of patent law with regulatory fluency and industry insight. Tara has led teams through all stages of litigation—from pre-suit investigation and strategy development through trial, appeal, and post-grant proceedings. Her litigation experience includes managing fact and expert discovery, taking and defending depositions, drafting and arguing dispositive motions, and examining witnesses at trial. She has appeared before federal district courts nationwide and the Federal Circuit and has experience coordinating parallel proceedings before the U.S. Patent and Trademark Office as a registered patent attorney.
Clients rely on Tara not only for her technical and legal acumen but her practical, business-focused guidance. She advises on patent portfolio development, freedom-to-operate analysis, licensing, regulatory exclusivity strategies, and IP aspects of transactions and product launches. Her ability to blend litigation precision with regulatory and commercial strategy makes her a valuable partner across the product lifecycle.
Whether defending a first-in-class therapeutic or supporting a competitive product launch, Tara brings relentless advocacy, strategic foresight, and a commitment to delivering results for her clients.
*Matter completed prior to joining Benesch.
Representative Experience
- Key member of trial team for a pharmaceutical company in ANDA litigation and on appeal with respect to numerous patents concerning an HIV antiviral.*
-
Key member of trial team that secured an invalidity ruling after appeal with respect to a patent in ANDA litigation concerning an ACE inhibitor.*
-
Key member of trial team that secured an invalidity ruling with respect to a patent in ANDA litigation concerning a steroid used to treat asthma.*
- Key member of team that secured victory on behalf of pharmaceutical company at the District Court and Federal Circuit levels, not only defeating a preliminary injunction motion but invalidating two patents upon summary judgment relating to a drug used to treat or prevent osteoporosis.*
- Member of team that secured a non-infringement ruling on summary judgment and on appeal with respect to a patent in ANDA litigation concerning a cephalasporin antibiotic.*
- Represented a pharmaceutical company in ANDA litigation involving numerous patents directed to a drug used to treat iron deficiency anemia in patients with chronic kidney disease (CKD).*
-
Represented pharmaceutical companies in ANDA litigation involving three polymorph patents relating to a coronary vasodilator used in pharmacologic stress testing.*
-
Represented pharmaceutical company in ANDA litigation involving formulation and device patents relating to a bronchodilator.*